Please ensure Javascript is enabled for purposes of website accessibility

Why Viking Therapeutics Stock Briefly Popped Today

By George Budwell - Jun 17, 2021 at 9:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An early-stage study gave investors reasons to cheer this morning.

What happened

Shares of the developmental-stage biotech Viking Therapeutics (VKTX -3.08%) jumped by as much as 11.2% in pre-market action Thursday morning. The company's shares perked up in response to an intriguing top-line readout for the experimental X-linked adrenoleukodystrophy (X-ALD) drug dubbed VK0214 in a phase 1 trial.

X-ALD is an inherited disease characterized by the gradual loss of a key structural protein (myelin) encasing the nerves in the brain and spinal cord. Previously, Viking was granted orphan drug designation by the Food and Drug Administration (FDA) for VK0214 as a treatment for this often fatal genetic disorder. 

A researcher inspecting a vial.

Image source: Getty Images.

So what

Turning to the details, Viking reported that this small phase 1 trial, consisting of healthy volunteers, yielded both favorable safety results (no adverse events), and some encouraging hints at efficacy. Most notably, patients treated with VK0214 in the study demonstrated reductions in low-density lipoprotein cholesterol (LDL-C), triglycerides, and apolipoprotein B across all dose levels. Viking thus plans to kick off a second phase 1 trial to evaluate the drug in X-ALD patients in the coming weeks.    

Now what

Is Viking's stock a strong buy in the wake of these early-stage trial results? The long and short of it is that the biotech's fate truly rests with its lead candidate VK2809; an experimental drug currently in mid-stage development for the high-value liver disease known as nonalcoholic steatohepatitis (NASH). VK0214, in short, is simply icing on the cake. So while these early trial results are definitely a step in the right direction, they don't necessary change the biotech's underlying investing thesis. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viking Therapeutics, Inc. Stock Quote
Viking Therapeutics, Inc.
VKTX
$3.77 (-3.08%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.